Your browser is no longer supported. Please, upgrade your browser.
APLT Applied Therapeutics, Inc. daily Stock Chart
Applied Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.69 Insider Own23.70% Shs Outstand17.31M Perf Week13.36%
Market Cap182.10M Forward P/E- EPS next Y-2.60 Insider Trans- Shs Float10.84M Perf Month5.73%
Income- PEG- EPS next Q-0.53 Inst Own36.80% Short Float0.18% Perf Quarter13.73%
Sales- P/S- EPS this Y-285.80% Inst Trans99.12% Short Ratio1.41 Perf Half Y-
Book/sh2.87 P/B3.67 EPS next Y-0.80% ROA- Target Price24.33 Perf Year-
Cash/sh2.37 P/C4.43 EPS next 5Y- ROE- 52W Range7.95 - 11.39 Perf YTD11.91%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.64% Beta-
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low32.33% ATR0.77
Employees9 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)59.02 Volatility6.78% 8.74%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume8.24 Prev Close9.81
ShortableYes LT Debt/Eq0.00 EarningsSep 20 BMO Payout- Avg Volume14.00K Price10.52
Recom1.50 SMA205.60% SMA5011.39% SMA20012.23% Volume115,266 Change7.24%
Jun-10-19Initiated Robert W. Baird Outperform $24
Jun-10-19Initiated Cowen Outperform
Jun-10-19Initiated Citigroup Buy $29
Sep-17-19 07:00AM  Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) GlobeNewswire
Sep-13-19 07:00AM  Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting GlobeNewswire
Sep-11-19 12:42PM  Top Ranked Momentum Stocks to Buy for September 11th Zacks
Sep-09-19 08:01AM  Top Ranked Momentum Stocks to Buy for September 9th Zacks
Sep-04-19 07:00AM  Applied Therapeutics Announces Initiation of Phase 3 Registrational Trial of AT-001 in Diabetic Cardiomyopathy (ARISE-HF) GlobeNewswire
Sep-03-19 10:45AM  Applied Therapeutics, Inc. (APLT) Shares March Higher, Can It Continue? Zacks -9.26%
Aug-28-19 07:00AM  Applied Therapeutics to Present at Bairds 2019 Global Healthcare Conference GlobeNewswire
Aug-14-19 03:51PM  What Percentage Of Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Do Insiders Own? Simply Wall St. -5.66%
Aug-12-19 07:00AM  Applied Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire +5.94%
Aug-08-19 07:00AM  Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study GlobeNewswire -8.11%
Jun-24-19 07:00AM  Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia GlobeNewswire
Jun-21-19 07:00AM  Applied Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire -6.59%
Jun-10-19 10:05AM  Applied Therapeutics Stock Jumps as Analysts Give It a Bullish Welcome +6.45%
Jun-07-19 07:30AM  Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy in Late Breaking Session at the American Diabetes Association 79th Annual Scientific Sessions GlobeNewswire
May-28-19 07:30AM  Applied Therapeutics Announces FDA Orphan Drug Designation for AT-007 in Galactosemia GlobeNewswire
May-24-19 07:00AM  Applied Therapeutics to Present Data at ESC-HF Highlighting AT-001, a Novel, Potent and Selective Aldose Reductase Inhibitor for Treatment of Diabetic Cardiomyopathy GlobeNewswire
May-20-19 10:15PM  Applied Therapeutics Inc (APLT) President and CEO Shoshana Shendelman Bought $1.3 million of Shares
May-08-19 07:11AM  Uber in drivers seat as IPO market gears up for busiest week since 2015 MarketWatch
May-07-19 10:46AM  The Applied Therapeutics IPO: What You Need To Know Benzinga
May-04-19 05:25PM  IPO Outlook For The Week: Uber (And 11 Others) Benzinga
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.